A Comparison of Intravenous Infliximab Versus Subcutaneous Infliximab on Remission Rates, Safety, Costs, Patient Preferences in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis

A Comparison of Intravenous Infliximab Versus Subcutaneous Infliximab on Remission Rates, Safety, Costs, Patient Preferences in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis

Background and Aims: Infliximab, widely used as a mainstay treatment of inflammatory bowel disease (IBD), is traditionally administered intravenously. The subcutaneous (SC) formulation appears to offer a more convenient route of administration. This is a systematic review and meta-analysis comparing...

Full description

Saved in:
Bibliographic Details
Main Authors: Alejandro Nieto Dominguez, Abhishek Bhurwal, Hemant Mutneja, Sarah E. Eichinger, Bhanu Pinnam, Daniel Guifarro Rivera, Chun-Wei Pan
Format: Article
Language:English
Published: Elsevier 2025-01-01
Series:Gastro Hep Advances
Subjects:
Crohn’s Disease
Ulcerative Colitis
CT-P13
Biologic Therapy
Online Access:http://www.sciencedirect.com/science/article/pii/S2772572324001845
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2772572324001845

Similar Items